VBIV - VBI Vaccines gains ahead of upcoming presentation on hep B shot

2023-06-07 13:57:29 ET

VBI Vaccines ( NASDAQ: VBIV ) added ~9% on Wednesday, albeit on below-average volumes, after the biotech announced an upcoming presentation on its Hepatitis B vaccine PreHevbrio at a European medical event later this month.

The Cambridge, Massachusetts-based biotech said that an abstract containing PreHevbrio data was accepted for a poster presentation at The International Liver Congress, taking place June 21-24.

At an oral presentation scheduled for June 21, Andrew Boyle, Medical Science Liaison ( MSL ) U.K, will discuss T-cell responses and the durability of immune responses following the immunization with PreHevbrio.

Cleared for use in multiple regions, including the U.S. and Europe, PreHevbrio contains three surface antigens of the hepatitis B virus.

More on VBI Vaccines

VBI Vaccines stock rises as hepatitis B shot PreHevbri gets approval in EU

VBI Vaccines: Recent Updates Have Fortified My Long-Term Outlook

For further details see: